Old Web
English
Sign In
Acemap
>
authorDetail
>
R Armstrong
R Armstrong
Alexion Pharmaceuticals
Eculizumab
Medicine
Clinical trial
complement inhibitor
Neuromyelitis optica
4
Papers
8
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial
2021
Multiple sclerosis and related disorders
Jacqueline Palace
Dean M. Wingerchuk
Kazuo Fujihara
Achim Berthele
Celia Oreja-Guevara
Ho Jin Kim
Ichiro Nakashima
Michael J. Levy
Murat Terzi
N. Totolyan
Shanthi Viswanathan
Kai-Chen Wang
Amy Pace
Marcus Yountz
Larisa Miller
R Armstrong
Sean J Pittock
Show All
Source
Cite
Save
Citations (5)
Long-term efficacy and safety of eculizumab monotherapy in AQP4+ neuromyelitis optica spectrum disorder (1578)
2021
Neurology
Sean J Pittock
Kazuo Fujihara
Jacqueline Palace
Achim Berthele
Ho Jin Kim
Celia Oreja-Guevara
Ichiro Nakashima
Michael J. Levy
Shulian Shang
Marcus Yountz
Larisa Miller
R Armstrong
Dean M. Wingerchuk
Show All
Source
Cite
Save
Citations (1)
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension:
2021
Multiple Sclerosis Journal
Sean J Pittock
Kazuo Fujihara
Jacqueline Palace
Achim Berthele
Ho Jin Kim
Celia Oreja-Guevara
Ichiro Nakashima
Michael J. Levy
Shulian Shang
Marcus Yountz
Larisa Miller
R Armstrong
Dean M. Wingerchuk
Show All
Source
Cite
Save
Citations (2)
Impact of Eculizumab on Disability Worsening and Quality of Life in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Results from the Phase 3 PREVENT Study (1658)
2020
Neurology
Jacqueline Palace
Sean J Pittock
Achim Berthele
Kazuo Fujihara
Ho Jin Kim
Michael J. Levy
Ichiro Nakashima
Murat Terzi
N. Totolyan
Shanthi Viswanathan
Kai-Chen Wang
Shulian Shang
Marcus Yountz
R Armstrong
Dean M. Wingerchuk
Show All
Source
Cite
Save
Citations (0)
1